-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
An “acquired” hemoglobin J variant in a sickle cell disease patient
Case report
(2409) Views (723) Full article downloads
Authors: Nawwar Swedan, Kathleen Nicol, Phylis Moder, Samir Kahwash
Published Date June 2008
Volume 2008:4(3) Pages 649 - 652
DOI: http://dx.doi.org/10.2147/TCRM.S6866
Nawwar Swedan1, Kathleen Nicol2, Phylis Moder2, Samir Kahwash2
1Fellow in Transfusion Medicine, Ohio State University, Columbus, Ohio; 2Department of Laboratory Medicine, Nationwide Children’s Hospital, Columbus, Ohio
Abstract: We report the case of a rare hemoglobin variant, “Hemoglobin J”, discovered while performing hemoglobin electrophoresis following exchange transfusion of a sickle cell disease patient. It is usual practice in our institution to confirm the hemoglobin S level in sickle cell disease patients after red cell exchange. The patient had received 5 red cell units and the source of this variant was traced back to two of those units. Due to the uncertain clinical impact of this variant, and the lack of specific guidelines, the two donors were deferred from future donations to our institution.
Keywords: hemoglobin J, sickle cell disease, transfusion
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- Tenofovir-associated bone density loss
- The benefits and risks of testosterone replacement therapy: a review
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




